These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6171533)

  • 1. Pharmacokinetics of low molecular (monovalent) dextran (Dx 1) in volunteers.
    Schwarz JA; Koch W; Bühler V; Kaumeier S
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):358-67. PubMed ID: 6171533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hapten inhibition: inhibition of antibody dependent dextran side effects by means of low molecular dextran (dextran 1) as a monovalent hapten].
    Schwarz JA
    Infusionsther Klin Ernahr; 1980 Apr; 7(2):105-8. PubMed ID: 6159322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of dextran-induced anaphylactic reactions by hapten inhibition. II. A comparison of the effects of 20 ml dextran 1, 15%, administered either admixed to or before dextran 70 or dextran 40.
    Renck H; Ljungström KG; Rosberg B; Dhunér KG; Dahl S
    Acta Chir Scand; 1983; 149(4):349-53. PubMed ID: 6193666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, pathomechanism and prevention of dextran-induced anaphylactoid / anaphylactic reactions in man.
    Hedin H; Richter W; Messmer K; Renck H; Ljungström KG; Laubenthal H
    Dev Biol Stand; 1980; 48():179-89. PubMed ID: 6168503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the kinetics and renal excretion of low and high molecular weight dextrans in preterm babies, newborns and young infants.
    Emmrich P; Baumann W; Stechele U
    Eur J Pediatr; 1977 Jul; 125(3):181-90. PubMed ID: 885145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetic considerations in the use of plasma expanders.
    Klotz U; Kroemer H
    Clin Pharmacokinet; 1987 Feb; 12(2):123-35. PubMed ID: 2435442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of dextran-induced anaphylactic reactions by hapten inhibition. III. A Scandinavian multicenter study on the effects of 20 ml dextran 1, 15%, administered before dextran 70 or dextran 40.
    Renck H; Ljungström KG; Hedin H; Richter W
    Acta Chir Scand; 1983; 149(4):355-60. PubMed ID: 6193667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of dextran-induced anaphylactic reactions by hapten inhibition. I. A Scandinavian multicenter study on the effects of 10 ml dextran 1, 15% administered before dextran 70 or dextran 40.
    Ljungström KG; Renck H; Hedin H; Richter W; Rosberg B
    Acta Chir Scand; 1983; 149(4):341-8. PubMed ID: 6193665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe dextran-induced anaphylactic/anaphylactoid reaction despite preventive hapten administration].
    Allhoff T; Lenhart FP
    Infusionsther Transfusionsmed; 1993 Dec; 20(6):301-6. PubMed ID: 7511449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of antibody mediated dextran side effects by hapten inhibition in dogs (author's transl)].
    Schwarz JA; Rother U; Koch W; Raschack M; Till G
    Anaesthesist; 1981 Jun; 30(6):297-303. PubMed ID: 6168208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The problem of dextran intolerance and its specific prevention with hapten inhibition. A part of the history of applied immunology].
    Ring J
    Fortschr Med; 1982 Nov; 100(41):1917-21. PubMed ID: 6185400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of etofylline after intravenous and oral administration to humans.
    Zuidema J; Verhoeven J; Merkus FW
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):310-3. PubMed ID: 7263108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathomechanisms of dextran-induced anaphylactoid/anaphylactic reactions in man.
    Hedin H; Richter W
    Int Arch Allergy Appl Immunol; 1982; 68(2):122-6. PubMed ID: 6176555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of dextran and the physiological background for the clinical use of rheomacrodex and macrodex.
    Hint H
    Acta Anaesthesiol Belg; 1968; 19(2):119-38. PubMed ID: 5746325
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevention of dextran-induced anaphylactoid reactions by preinjection of 20 ml hapten in 12 000 patients in Switzerland].
    Gruber UF; Wettler H; Allemann U; Gerber H; Laubenthal H; Messmer K
    Schweiz Rundsch Med Prax; 1982 Jun; 71(26):1092-100. PubMed ID: 6181497
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection.
    Hartman NR; Johns DG; Mitsuya H
    AIDS Res Hum Retroviruses; 1990 Jun; 6(6):805-12. PubMed ID: 1694681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of dextran in relation to other colloids--ten years experience with hapten inhibition.
    Ljungström KG
    Infusionsther Transfusionsmed; 1993 Oct; 20(5):206-10. PubMed ID: 7508309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of 3H-dextran in two colonies of Wistar rats after intravenous injection.
    Hanahoe TH; Wright JD
    Int Arch Allergy Appl Immunol; 1983; 72(4):366-8. PubMed ID: 6196304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious complications with dextran-70 despite hapten prophylaxis. Is it best avoided prior to delivery?
    Berg EM; Fasting S; Sellevold OF
    Anaesthesia; 1991 Dec; 46(12):1033-5. PubMed ID: 1723580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialysed patients.
    Fleming LW; Stewart WK; Parratt D
    Nephrol Dial Transplant; 1992; 7(1):35-9. PubMed ID: 1374865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.